nach oben

Erschienen in:

01.10.2023 | Clinical study

PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

There is a higher prevalence of immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) during first-line therapy with immune checkpoint inhibitors (ICIs) than with subsequent lines of therapy, according to findings of a systematic review and meta-analysis published in Frontiers in Oncology . …

PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events Frontiers in Oncology : 29 Sep 2023. Available from: URL: https://doi.org/10.3389/fonc.2023.1191681

Titel: PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy
Publikationsdatum: 01.10.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-48202-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Bupropion/nicotine/varenicline

Iohexol

Antineoplastics

Multiple drugs

Bupivacaine/morphine

Infliximab